VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MIRM
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
MIRMMirum Pharmaceuticals, Inc.
$91.95$5.6B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
MIRM logo

Mirum Pharmaceuticals, Inc.

MIRM
NASDAQ · Rare Disease Biotech
$91.95
At close - Nov 17, 4:00 PM EST - USD
Market Cap$5.61B
P/E-6.7x
52W High$130.00
Volume377.67K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Revenue Scaling Rapidly But Losses and Negative Equity Persist

Mirum's revenue has grown rapidly, reaching $185.7M in 2026Q3 with a 39.6% year-over-year increase, while gross margins have held steady in the 81% to 83% range, suggesting durable unit economics.

GrowthDecelerating
ProfitabilityWeak
ValuationExpensive
TechnicalsWeak
Explore valuation models
MARKET ACTION

MIRM price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

4/12 Beats

EPS beat 4 of last 12 quarters

02

Valuation risk

-116% Peers

P/E is 116% below peer median

03

Market leadership

RS 59 · Avg

Average momentum (RS Rating: 59)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 3
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue reached $185.7M in 2026Q3, up 39.6% year over year and decelerating from a 107.7% peak in 2024Q2, while gross margin held near 81% yet operating margin stayed negative at -32.2%, with a one-time $790.2M net loss in 2026Q1 warranting further investigation.

Analyst Consensus+68.5% target
Buy(18 analysts)
18 Buy0 Hold0 Sell

The Bull Case

Upside Catalysts

Pivotal late-breaking results

Mirum Pharmaceuticals and Incyte announced pivotal late-breaking results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva, accepted for presentation at ENDO 2026.

Positive stock analysis coverage

MarketBeat provides the latest MIRM stock analysis, price targets, earnings estimates, and headlines, indicating ongoing investor interest and potential upside.

Investor relations engagement

Mirum maintains active investor relations with accessible contacts and stock quote information, suggesting transparency and engagement with shareholders.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
MIRM+17.78%
S&P 500 (^GSPC)+7.21%
1-Year Return
MIRM+27.34%
S&P 500 (^GSPC)+10.03%
3-Year Return
MIRM+184.50%
S&P 500 (^GSPC)+50.86%
5-Year Return
MIRM+494.76%
S&P 500 (^GSPC)+62.97%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E
-6.8x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-6.8x
N/A
N/A
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
210.6x
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$1.58-98.3%
Base (Fair)$105.29+12.0%
Bull$4.83-94.7%
$1.58 Bear$105.29 Base$4.83 Bull
Current Market Price: $91.95
Trades at a 12.7% discount to Base DCF ($105.29)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$521M+54.7% YoY
Net income FY25
-$23M+73.4% YoY
Free cash flow FY25
$55M+488.0% YoY
Operating margin FY25
-4.2%+21.8 pts YoY
ROIC (FY25)-5%
Avg ROIC 5Y-74.6%
ROE (TTM)-734%
Piotroski Score6 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate4/12 (33%)
Revenue Beat Rate8/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 3, 2026
-$0.87-78.7%
vs -$0.49
$186M+4.3%
vs $178M
Q3 2026
Aug 5, 2026
-$1.06-42.8%
vs -$0.74
$176M+5.9%
vs $166M
Q2 2026
May 6, 2026
-$13.43-3257.5%
vs -$0.40
$160M+7.9%
vs $148M
Q1 2026
Feb 25, 2026
-$0.11-650.0%
vs $0.02
$149M+4.5%
vs $143M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·3d ago
AMG TimesSquare Small Cap Growth Fund Q3 2026 Portfolio Activity

During this quarter, AMG TimesSquare Small Cap Growth Fund outperformed the Russell 2000® Growth Index as the market rewarded the quality characteristics our process emphasizes. We benefited most from our holdings in the Information Technology, Financials, and Consumer Staples sectors, while positioning in the Industrials, Health Care, and Consumer Discretionary sectors offset part of the gain. Each of our largest contributors was driven by company-specific fundamentals, including solid results and business momentum, and, in two cases, making acquisitions we viewed as strategically or financially attractive.

Business Wire·6d ago
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Zacks Investment Research·Nov 11, 2026
MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV

Mirum's brelovitug marks a second phase III win in chronic HDV, bringing the company closer to a planned 2027 BLA filing with the FDA.

Reuters·Nov 10, 2026
Mirum's liver infection drug lowers virus levels in second late-stage study

Mirum's liver infection drug lowers virus levels in second late-stage study

Filtered for Mirum Pharmaceuticals, Inc.More Headlines
04

Compare before deciding

Benchmark MIRM against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Mirum Pharmaceuticals, Inc. (MIRM)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
MIRM logoMIRMMirum Pharmaceuticals, Inc.Current
$91.95$5.61B-6.7254.74%-134.75%-734%—
ALNY logoALNYAlnylam Pharmaceuticals, Inc.
$156.50$20.89B7.9365.19%54.34%159.72%—
RARE logoRAREUltragenyx Pharmaceutical Inc.
$16.70$1.64B-3.2520.13%-71.78%——
ACAD logoACADACADIA Pharmaceuticals Inc.
$18.32$3.14B8.8711.87%30.13%28.03%—
PTCT logoPTCTPTC Therapeutics, Inc.
$60.36$5.01B-47.55114.51%-9.17%——
KRYS logoKRYSKrystal Biotech, Inc.
$298.55$8.8B40.8933.94%47.91%17.02%—

Compare MIRM vs Peers

Mirum Pharmaceuticals, Inc. (MIRM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ALNY

Most directly comparable listed peer for MIRM.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare MIRM against a more recognizable public peer.

Peer Set

Compare Top 5

vs ALNY, RARE, ACAD, PTCT

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

MIRM SEC Filings & Documents

Mirum Pharmaceuticals, Inc. (MIRM) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 3, 2026·SEC

Material company update

Oct 26, 2026·SEC

Material company update

Oct 13, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 25, 2026·SEC

FY 2025

Feb 26, 2025·SEC

FY 2024

Mar 15, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 3, 2026·SEC

FY 2026

Aug 5, 2026·SEC

FY 2026

May 6, 2026·SEC

Get notified when MIRM posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

MIRM Frequently Asked Questions

Mirum Pharmaceuticals, Inc. (MIRM) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Mirum Pharmaceuticals, Inc.'s revenue?

Mirum Pharmaceuticals, Inc. (MIRM) reported $670.8M in revenue over the trailing twelve months. Revenue was $521.3M in fiscal year 2025.

How fast is Mirum Pharmaceuticals, Inc. growing?

Mirum Pharmaceuticals, Inc. (MIRM) grew revenue by 42.2% over the trailing twelve months, compared with the twelve months before.

Is MIRM profitable?

No. Mirum Pharmaceuticals, Inc. (MIRM) reported a net loss of $903.9M over the trailing twelve months.

Dividend & Returns
What is MIRM's return on equity?

Mirum Pharmaceuticals, Inc. (MIRM) had a return on equity (ROE) of -734.0% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Mirum Pharmaceuticals, Inc.'s free cash flow?

Mirum Pharmaceuticals, Inc. (MIRM) had negative free cash flow of $503.3M over the trailing twelve months.

What if you invested $1,000 in MIRM back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →